Cue Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Cue Biopharma, Inc. carries a market capitalization of 86.33M, placing it among publicly traded companies globally. Its enterprise value stands at 150.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 86.33M |
| Enterprise Value | 150.72M |
Share Statistics
Cue Biopharma, Inc. currently has 5.23M shares outstanding.
| Shares Outstanding | 5.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.79, and the price-to-book ratio stands at 71.45.
| PE Ratio | N/A |
| PS Ratio | 3.79 |
| PB Ratio | 71.45 |
| P/TBV Ratio | 71.45 |
| P/FCF Ratio | -2.88 |
| P/OCF Ratio | -2.86 |
Enterprise Valuation
| EV / Sales | 4.00 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cue Biopharma, Inc. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 133.20, indicating elevated leverage, while an interest coverage ratio of -707.44 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.25 |
| Quick Ratio | 1.16 |
| Debt / Equity | 133.20 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | -707.44 |
Financial Efficiency
| Return on Equity (ROE) | -1,603.48 |
| Return on Assets (ROA) | -459.60 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -88.74 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Cue Biopharma, Inc.'s stock has gained approximately 58.69565% over the past 52 weeks. The 50-day moving average sits at 29.33, while the 200-day moving average is 19.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | 58.69565% |
| 50-Day Moving Average | 29.33 |
| 200-Day Moving Average | 19.74 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cue Biopharma, Inc. generated 37.65M in revenue and converted that into -164.11M in net income, yielding earnings per share of -36.08. EBITDA reached -95.50M, while operating income came in at -98.64M.
| Revenue | 37.65M |
| Gross Profit | N/A |
| Operating Income | -98.64M |
| Pretax Income | -163.61M |
| Net Income | -164.11M |
| EBITDA | -95.50M |
| EBIT | -98.64M |
| Earnings Per Share (EPS) | -36.08 |
Balance Sheet
Cue Biopharma, Inc. holds 17.39M in cash and equivalents against 3.08M in total debt, resulting in a net debt position of -17.39M. Total book value stands at 2.31M, with working capital of 5.41M providing operational flexibility.
| Cash & Cash Equivalents | 17.39M |
| Total Debt | 3.08M |
| Net Debt | -17.39M |
| Equity (Book Value) | 2.31M |
| Book Value Per Share | 0.44 |
| Working Capital | 5.41M |
Cash Flow
Cue Biopharma, Inc. produced -50.05M in operating cash flow over the past twelve months. After subtracting -121,000.00 in capital expenditures, free cash flow totaled -50.17M - equivalent to -11.08 per share.
| Operating Cash Flow | -50.05M |
| Capital Expenditures | -121,000.00 |
| Free Cash Flow | -50.17M |
| FCF Per Share | -11.08 |
Margins
Cue Biopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -261.97 and net profit margin of -435.83 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -261.97 |
| Pretax Margin | -434.50 |
| Profit Margin | -435.83 |
| EBITDA Margin | -253.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.13 |
| FCF Yield | -34.78 |
Stock Splits
Cue Biopharma, Inc.'s most recent stock split took place on April 24, 2026 with a 30:1 split ratio.
| Last Split Date | 4/24/2026 |
| Split Ratio | 30:1 |
Scores
Cue Biopharma, Inc. posts an Altman Z-Score of -29.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.69 |